Coronavirus disease 2019 has been recently classified as pandemic infection by the World Health Organization. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. It is unclear whether a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects during biological therapy and current evidence does not support treatment suspension. However, during pandemic, the start of treatment with immunosuppressive drugs and biologics should be postponed whenever possible and based on an individual risk assessment. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Serum antibody testing, when available, could provide evidence of infection as well as identify patients already immune to the disease.Keywords: COVID-19, Biologic, screening, IBD, Crohn’s disease, Ulcerative Colitis
Coronavirus disease 2019 has been recently classified as a pandemic infection by the World Health Organization and it can present with different clinical manifestations: as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate, with severe clinical courses and deaths being more likely in older patients with underlying comorbidities compared to mild cases . Also, male gender seems to be at higher risk of morbidity and mortality. Due to the rapid spread of the disease, governments and the medical community are taking measures to prevent transmission, from common sense recommendations to radical quarantine measures . Accumulating evidence shows that patients with COVID-19 infection may also experience gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal discomfort prior to the common respiratory symptoms [3,4]. The potential clinical implications are relevant as COVID19 may have an impact on bowel function and may increase the risk of transmission through the faecal–oral route . To corroborate, recent studies found that in more than 20% of SARS-CoV-2 patients the viral RNA remained positive in feces even after negative conversion of the viral RNA in the respiratory tract, indicating that the gastrointestinal viral infection and the potential fecal-oral transmission can last even after viral clearance in the respiratory tract . In keeping, it has been recommended that rRT-PCR testing for SARS-CoV-2 from feces should be performed routinely in SARS-CoV-2 patients, and Transmission-Based Precautions for hospitalized SARS-CoV-2 patients should continue if feces test positive by rRT-PCR testing.
However, the impact of the COVID-19 on chronic relapsing gastrointestinal disease is unknown. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. Elective outpatients clinics should be reorganized by institution of telemedicine services, patients should continue their medications and access to infusion centres be retained, assuming actions to avoid infection outbreaks are taken in place. Current recommendation suggests postponing the start of treatment with immunosuppressive drugs and biologics, whenever possible, based on an individual risk assessment during the COVID19 pandemic , , . However, since postponing the drug start is not always possible depending on the clinical activity of the patients, particular measures should be considered in order to reduce COVID-19–related risks. A viral screen is commonly suggested before starting biologics  due to the higher risk of serious and opportunistic infections in IBD patients , , , that becomes particularly high in patients older than 50 years [12,13].
Since it is expected that a same higher risk might occur in SARS-CoV-2, we believe that, at least temporarily, there is an urgent need to update the current recommendations for pre-biological screening . Although there is no data showing that immunosuppressive/immunomodulatory therapies are associated with poor prognosis of COVID-19 infection and immunomodulation is likely to be beneficial in a subgroup of severe COVID-19 with hyper-inflammatory syndrome as suggested by recent uncontrolled data , a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects starting biological therapy. Moreover, inhibiting anti-viral immunity by broad immunosuppression could delay virus clearance and perpetuate symptoms and illness .
Given the uncertainties linked to the rapid and global COVID-19 outbreak it is clear that efforts should be focused on the best care we can provide to our IBD patients in general and particularly to those under immunosuppressive/ immunomodulatory treatment . These patients might have higher viral load, prolonged viral shedding and impaired antibody response. Raised serum antibodies against nucleoprotein (NP) and spike protein receptor binding domain (RBD) of SARSCoV-2 have been shown in most patients at 10 days or later after symptoms onset with a correlation between antibody response and neutralising antibody titre . Detecting serum IgM and IgG antibodies can provide historic information about viral exposure as well as diagnostic evidence.
Knowledge of virus dynamics and host response is crucial to fully evaluate the impact of immunosuppressive therapies on the clinical course of COVID-19 in IBD patients and to provide management guidance to healthcare professionals.
In conclusion, before starting biological therapy, until new data will be available, using a pragmatic approach, the physician should screen all patients for active COVID-19 by RT-PCR, even without clinical suspicion of infection. Thus, we suggest updating the common screening recommended prior to biological therapy in IBD patients (Table 1 )  adding COVID-19 RT-PCR and, when available, antibody profile. Moreover, based on current evidence, screening for COVID-19 in patients who are receiving either biological/immunodulatory treatments or are on conventional therapies should not be recommended and current medications maintained.
Specific author contributions
FZ, AB, ES: study concept, critical review of manuscript, drafting and finalization of manuscriptGo to:
Conflict of interest
Nothing to declare.Go to:
- 1. Lai C.C., Liu Y.H., Wang C.Y. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;(Mar 4) doi: 10.1016/j.jmii.2020.02.012. pii: S1684-1182(20)30040-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 2. Xiao Y., Torok M.E. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020;(Mar 5) doi: 10.1016/S1473-3099(20)30152-3. pii: S1473-3099(20)30152-3. [CrossRef] [Google Scholar]
- 3. Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;(Mar 3) doi: 10.1053/j.gastro.2020.02.054. pii: S0016-5085(20)30281-X. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 4. Xiao F., Tang M., Zheng X. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;(Mar 3) doi: 10.1053/j.gastro.2020.02.055. pii: S0016-5085(20)30282-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 5. 1st Interview COVID-19 ECCO Taskforce. ECCO crisis task force. https://www.ecco-ibd.eu/images/6_Publication/6_8_Surveys/1st_interview_COVID-19%20ECCOTaskforce_published.pdf (Accessed 13 March 2020).
- 6. 2nd Interview COVID-19 ECCO Taskforce. https://ecco-ibd.eu/images/6_Publication/6_8_Surveys/2nd_Interview_COVID-19_ECCO_Taskforce_published.pdf (Accessed 20 March 2020)
- 7. Ungaro R.C., Sullivan T., Colombel J.-.F., Patel G. What should gastroenterologists and patients know about COVID-19? Clin Gastroenterol Hepatol. 2020;(Mar 17) doi: 10.1016/j.cgh.2020.03.020. pii: S1542-3565(20)30330-X. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 8. Lamb C.A., Kennedy N.A., Raine T. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. doi: 10.1136/gutjnl-2019-318484. 2019/09/29. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 9. Ford A.C., Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276. doi: 10.1038/ajg.2013.138. 2013/05/08. [PubMed] [CrossRef] [Google Scholar]
- 10. Osterman M.T., Sandborn W.J., Colombel J.F. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–1815. doi: 10.1038/ajg.2016.433. 2016/09/28. [PubMed] [CrossRef] [Google Scholar]
- 11. Singh S., Murad M.H., Fumery M. First- and Second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;(Jan 13) doi: 10.1016/j.cgh.2020.01.008. pii: S1542-3565(20)30044-6. [PubMed] [CrossRef] [Google Scholar]
- 12. Naganuma M., Kunisaki R., Yoshimura N. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 2013;48:595–600. doi: 10.1007/s00535-012-0686-9. 2012/10/12. [PubMed] [CrossRef] [Google Scholar]
- 13. Toruner M., Loftus E.V., Jr., Harmsen W.S. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936. doi: 10.1053/j.gastro.2008.01.012. 2008/02/26. [PubMed] [CrossRef] [Google Scholar]
- 14. Zingone F., Edoardo V.S. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020;(Mar 25) doi: 10.1016/S2468-1253(20)30085-6. pii: S2468-1253(20)30085-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 15. Meta P.M., McAuley D.F., Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;(Mar 16) doi: 10.1016/S0140-6736(20)30628-0. pii: S0140-6736(20)30628-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 16. Ritchie A., Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020 (published online March 24, 2020) [PMC free article] [PubMed] [Google Scholar]
- 17. To K.K.-W., Tsang O.T.-Y., Leung W.-.S. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 (published online March 23.) [PMC free article] [PubMed] [Google Scholar]
Zingone F, Buda A, Savarino EV. Starting a biologic therapy in IBD patients amidst COVID-19: hold, careful monitoring or testing? [published online ahead of print, 2020 May 19]. J Crohns Colitis. 2020;jjaa102. doi:10.1093/ecco-jcc/jjaa102